Abstract 5220
Background
The Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 system (CRISPR/Cas9 system), is the defense mechanism in Streptococcus pyogenes against viruses, now it is widely used by researchers as a precise gene editing tool that allows a targeted genomic editing with the least possible off targets. Colorectal cancer (CRC) has recently become a devastating disease with mortality rate exceeded 9% in 2018, where the survival rate worsens once it metastasizes to vital organs such as the liver or lungs. Chemokines are one of the key players that promote cancer cell metastasis in some types of cancers, including colorectal cancer, where increasing evidence shows that CRC accumulates invasive and metastatic capacities through tumor microenvironment. In the light of this, we aimed at understanding the tumor microenvironment to achieve a comprehensive therapy, aiming in preventing early metastasis.
Methods
Microarray was done by our research group on early metastasized CRC cells to liver in a group of rats with CRC. In silico sgRNA CRISPR designing tools were used to design a sgRNA targeting C-C motif chemokine ligand 4 (CCL4) gene. The insert was ligated into a Cas9 expressing plasmid and transformed into E.coli. The Plasmid was then extracted and sequenced. CRC cells were transfected with the cloned plasmid. Functional assays were performed.
Results
Microarray results showed that CCL4 was highly expressed in early metastasized CRC cells to liver that gives a hypothesis that it has a role in cancer progression. Sequencing results confirmed a successful sgRNA insertion into the Cas9 plasmid. In addition, knocking out the expression of CCL4 in CRC cells significantly inhibited the cellular metabolic activity compared to cells transfected with empty plasmid. Furthermore, the ability of CRC cells to proliferate and to form colonies was dramatically decreased in response to CCL4 knockout in comparison to that transfected with empty plasmid.
Conclusions
CCL4 has oncogenic effect on CRC by its positive effect on cell proliferation properties and metabolic activity. The results indicate that CCL4 may act as a promising target for further studies to reveal its downstream impact on CRC progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hassan Adwan, German University in Cairo, Cairo, Egypt.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3266 - Morphology of tumor-associated macrophages dictates the prognosis of patients with colorectal liver metastases.
Presenter: Matteo Donadon
Session: Poster Display session 2
Resources:
Abstract
1694 - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D
Presenter: Richard Kim
Session: Poster Display session 2
Resources:
Abstract
908 - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer
Presenter: Hui Li
Session: Poster Display session 2
Resources:
Abstract
3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.
Presenter: Zafeiris Zafeiriou
Session: Poster Display session 2
Resources:
Abstract
5416 - The SAFFO study: Sex-related prognostic role And cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Presenter: Camilla Lisanti
Session: Poster Display session 2
Resources:
Abstract
2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase
Presenter: Marwan Fakih
Session: Poster Display session 2
Resources:
Abstract
4000 - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: Poster Display session 2
Resources:
Abstract
2223 - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer
Presenter: Wataru Okamoto
Session: Poster Display session 2
Resources:
Abstract
2569 - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Presenter: Kanan Alshammari
Session: Poster Display session 2
Resources:
Abstract
5402 - Microsatellite instability and immunogenicity in colorectal cancer – do resident memory Tcells (Trm) play a role in colorectal cancer
Presenter: Wei Toh
Session: Poster Display session 2
Resources:
Abstract